AmnioGraft Available for the Ocular Treatment of Stevens-Johnson Syndrome

 -New larger designed size provides more coverage to help heal the ocular surface -

MIAMI, Fla., December 11, 2012 – Bio-Tissue, Inc., an ophthalmic biologic therapeutics company, today announced the availability of AmnioGraft® AG-5050, a new larger designed size of its AmnioGraft, for the treatment of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Bio-Tissue’s AmnioGraft is a Biologic Ocular Transplantation Graft comprised of amniotic membrane that is used by ophthalmologists around the world to protect, repair and heal damaged eye surfaces.

Stevens-Johnson syndrome presents a medical emergency that usually requires hospitalization. Between 50 percent and 80 percent of patients with Stevens-Johnson syndrome experience eye problems, ranging from mild dry eye to severe scarring that can cause blindness.  

“Stevens-Johnson syndrome and Toxic Epidermal Necrolysis are horrible diseases— when they affect the eyes. They are the worst diseases one can see and can lead to blindness if not treated,” said Scheffer C. G. Tseng, MD, PhD. “When patients are treated early, cryopreserved amniotic membrane works very well in the acute treatment of the eye for these diseases as it has therapeutic qualities that help the eye surface heal faster. Cryopreserved amniotic membrane has changed how we treat patients with Stevens-Johnson syndrome/Toxic Epidermal Necrolysis and is helping to save sight.”

The new Bio-Tissue AmnioGraft AG-5050 available for Stevens-Johnson syndrome/Toxic Epidermal Necrolysis is 5.0cm x 5.0cm to provide greater coverage to help heal the ocular surface inflammation and ulceration of patients with Stevens-Johnson syndrome/Toxic Epidermal Necrolysis. AmnioGraft delivers the amniotic membrane’s unique wound repair and healing actions that reduce inflammation, reduce the formation of abnormal blood vessels, prevent scarring, and minimize patient pain.